Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Pol Polyprotein Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Pol Polyprotein Products under Development by Stage of Development | 7 | 1 |
| Pol Polyprotein Products under Development by Therapy Area | 8 | 1 |
| Pol Polyprotein Products under Development by Indication | 9 | 1 |
| Pol Polyprotein Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Pol Polyprotein Products under Development by Companies | 12 | 2 |
| Pol Polyprotein Products under Development by Universities/Institutes | 14 | 2 |
| Pol Polyprotein Therapeutics Assessment | 16 | 5 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Route of Administration | 17 | 2 |
| Assessment by Molecule Type | 19 | 2 |
| Pol Polyprotein Companies Involved in Therapeutics Development | 21 | 3 |
| GeoVax Labs, Inc. | 21 | 1 |
| Inovio Pharmaceuticals, Inc. | 22 | 1 |
| Johnson &Johnson | 23 | 1 |
| Pol Polyprotein Drug Profiles | 24 | 14 |
| GOVXB-11 Drug Profile | 24 | 3 |
| GOVXC-11 Drug Profile | 27 | 1 |
| GOVXC-21 Drug Profile | 28 | 1 |
| HIV [serotype Ad26] (tetravalent) vaccine Drug Profile | 29 | 1 |
| HIV-1 (bivalent) vaccine Drug Profile | 30 | 1 |
| HIV-1 vaccine 11 Drug Profile | 31 | 1 |
| HIV-1 vaccine 5 Drug Profile | 32 | 1 |
| PENNVAX-B Drug Profile | 33 | 3 |
| PENNVAX-GP Drug Profile | 36 | 2 |
| Pol Polyprotein Dormant Projects | 38 | 1 |
| Pol Polyprotein Featured News &Press Releases | 39 | 12 |
| May 18, 2016: GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 | 39 | 1 |
| Apr 14, 2016: GeoVax Awarded $1.4M NIH Grant | 40 | 1 |
| Mar 07, 2016: Strong Protection Elicited by an Immunodeficiency Virus Vaccine in Non-Human Primates | 40 | 1 |
| Sep 08, 2015: Inovio Pharmaceuticals Announces First Patient Dosed With Universal HIV Vaccine | 41 | 1 |
| Apr 14, 2015: GeoVax to Seek Dual Pathway for Advancing Its HIV Preventive Vaccine | 42 | 1 |
| Apr 09, 2015: GeoVax Provides Details of Presentation at World Vaccine Congress | 42 | 1 |
| Apr 01, 2015: GeoVax Provides Update on Its HIV Vaccine Program | 43 | 1 |
| Mar 16, 2015: Inovio Pharmaceuticals and Academic Collaborators Receive $16 Million HIV Grant From National Institute of Allergy and Infectious Diseases | 44 | 1 |
| Jan 06, 2015: Inovio Pharmaceuticals HIV Immunotherapy Shows Characteristics Considered Vital to Treating HIV | 45 | 1 |
| Oct 29, 2014: GeoVax Presents HIV Vaccine Clinical Trial Data | 46 | 1 |
| Jul 30, 2014: GeoVax Awarded Small Business Innovative Research (SBIR) Grant from National Institutes of Health | 47 | 1 |
| Jan 23, 2014: GeoVax Announces Publication of Phase 2a Clinical Trial in The Journal of Infectious Diseases | 47 | 1 |
| Jan 13, 2014: GeoVax Announces Preliminary Top-Line Results for Phase 1 Therapeutic Vaccine Trial in HIV-Infected Patients | 48 | 1 |
| Oct 09, 2013: GeoVax DNA/MVA Vaccine Elicits Sustained Antibody Responses to HIV | 49 | 1 |
| Jan 10, 2013: GeoVax Announces Enrollment Completion For Phase I/II Clinical Trial For HIV/AIDS Therapeutic Vaccine | 50 | 1 |
| Appendix | 51 | 2 |
| Methodology | 51 | 1 |
| Coverage | 51 | 1 |
| Secondary Research | 51 | 1 |
| Primary Research | 51 | 1 |
| Expert Panel Validation | 51 | 1 |
| Contact Us | 51 | 1 |
| Disclaimer | 52 | 1 |